Fractyl Health, Inc. (GUTS)
| Market Cap | 104.90M +46.7% |
| Revenue (ttm) | n/a |
| Net Income | -105.65M |
| EPS | -0.81 |
| Shares Out | 159.18M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,380,669 |
| Open | 0.7406 |
| Previous Close | 0.7418 |
| Day's Range | 0.6450 - 0.7590 |
| 52-Week Range | 0.3772 - 2.4450 |
| Beta | 2.32 |
| Analysts | Strong Buy |
| Price Target | 5.03 (+663.28%) |
| Earnings Date | Aug 10, 2026 |
About GUTS
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably alteri... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for GUTS stock is "Strong Buy." The 12-month stock price target is $5.03, which is an increase of 663.28% from the latest price.
News
Fractyl Health Proxy statement: Proxy filing
Fractyl Health filed a proxy statement on August 24, 2026, providing details for shareholder voting and corporate governance matters.
Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance
BURLINGTON, Mass., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical stage metabolic therapeutics company focused on pioneering novel approache...
Fractyl Health Proxy statement: Proxy filing
Fractyl Health filed a proxy statement on August 14, 2026, providing details for shareholder voting and corporate governance matters.
Fractyl Health Transcript: Canaccord Genuity's 46th Annual Growth Conference
Durable therapies for obesity and diabetes are advancing, with Revita showing strong weight maintenance in clinical trials and pivotal data expected soon. Commercialization will focus on specialized centers, leveraging partnerships and existing clinical networks. Rejuva gene therapy is entering first-in-human trials this year.
Fractyl Health reports Q2 EPS (16c), consensus (14c)
“With one-year randomized data for the REMAIN-1 Midpoint Cohort and open label data for REVEAL-1 Cohort, we have the clearest evidence yet that a single Revita procedure can meaningfully reduce…
Fractyl Health Earnings Call Transcript: Q2 2026
Revita maintained over 80% of GLP-1-induced weight loss at one year with a strong safety profile, while pivotal trial data and a potential FDA De Novo submission are expected in Q4 2026. Cash runway extends into early 2027, supporting both Revita and Rejuva programs.
Fractyl Health Earnings release: Q2 2026
Fractyl Health released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Fractyl Health Quarterly report: Q2 2026
Fractyl Health has published its Q2 2026 quarterly earnings report on August 10, 2026.
Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026
BURLINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approache...
Fractyl Health to Participate in Upcoming Investor Events
BURLINGTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approache...
Fractyl Health Transcript: Study result
One-year data from the REMAIN-1 midpoint cohort show Revita enables patients to maintain up to 84% of GLP-1-induced weight loss, with a favorable safety profile and minimal adverse events. Durable, drug-free weight maintenance is achievable, supporting broad outpatient use and strong patient demand.
Fractyl Health Press release: Study result
Fractyl Health issued a press release on July 15, 2026, disclosing material business information to investors.
Fractyl Health Slides: Study result
Fractyl Health has posted slides in relation to its latest quarterly earnings report, which was published on July 15, 2026.
Fractyl Health reports results from REMAIN-1 Midpoint Cohort
Fractyl Health (GUTS) announced positive one-year results from its REMAIN-1 Midpoint Cohort. The new results reinforce the potential of the Revita DMR System to be the first durable procedural therapy...
Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation
Up to 84% of GLP-1 induced weight loss retained with Revita® versus 46% with sham at one year in patients receiving complete duodenal ablations Next anticipated Revita® milestones are topline six-mont...
Craig-Hallum bullish on Fractyl Health, initiates with a Buy
As previously reported, Craig-Hallum initiated coverage of Fractyl Health (GUTS) with a Buy rating and $4 price target Fractyl Health is a med-tech company developing Revita, an endoscopic procedure d...
Fractyl Health initiated with a Buy at Craig-Hallum
Craig-Hallum initiated coverage of Fractyl Health (GUTS) with a Buy rating and $4 price target
Fractyl Health Transcript: AGM 2026
The meeting covered board introductions, voting on director elections and auditor ratification, and outlined procedures for participation. Both proposals passed, with final results to be published soon. No questions were submitted during the Q&A.
Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
Participants retained ~78% of GLP-1 induced total body weight loss one year after discontinuation and a single Revita procedure
Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy
BURLINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approache...
Fractyl Health Transcript: Bank of America Global Healthcare Conference 2026
Revita aims to provide a durable, non-pharmacologic weight maintenance solution for obesity and type 2 diabetes, with pivotal clinical data and a regulatory filing expected by year-end. The company is targeting a focused commercial launch and is well-funded into 2027, while also advancing its gene therapy pipeline.
Fractyl Health reports Q1 EPS 6c, consensus (16c)
“We believe Revita has the potential to offer a transformational new approach to durable weight maintenance and a clinically needed off ramp from GLP-1 therapy. Our first quarter results reflect…
Fractyl Health Earnings Call Transcript: Q1 2026
Q1 2026 saw improved financials and strong clinical progress, with pivotal Revita trial data expected in early Q4 and Rejuva gene therapy advancing to first-in-human studies. Cash runway extends into early 2027, with no capital raise planned before pivotal data.
Fractyl Health Earnings release: Q1 2026
Fractyl Health released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Fractyl Health Quarterly report: Q1 2026
Fractyl Health has published its Q1 2026 quarterly earnings report on May 12, 2026.